by Team Small News | Jun 1, 2025 | Pfizer, Pharma
A promising experimental treatment for breast cancer, developed by Pfizer and Arvinas, has shown significant results in delaying the progression of the disease. The treatment, called vepdegestrant, was tested in a clinical trial of 624 patients with a specific type of... by Team Small News | May 31, 2025 | Pfizer, Pharma
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting featured significant presentations from major pharmaceutical companies, including Pfizer, AstraZeneca, and Daiichi Sankyo. The meeting highlighted new data on innovative cancer treatments, showcasing... by Team Small News | May 30, 2025 | Pfizer, Pharma
Pfizer’s recent failure to gain FDA approval for its oral obesity drug, danuglipron, has raised concerns about the company’s research and development pipeline. Danuglipron was expected to be a major contributor to Pfizer’s revenue growth, but its... by Team Small News | May 27, 2025 | Pfizer, Pharma
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market study, conducted by USD Analytics, provides a comprehensive analysis of the market, covering over 143 pages. The report describes the product and industry scope, market prognosis, and status for 2025-2034. The... by Team Small News | May 23, 2025 | Pfizer, Pharma
Astellas and Pfizer have released five-year follow-up results from the open-label extension of the Phase III ARCHES trial, which evaluated the effectiveness of Xtandi (enzalutamide) in combination with androgen deprivation therapy (ADT) in men with metastatic... by Team Small News | May 21, 2025 | Pfizer, Pharma
South Korea’s SK bioscience has emerged victorious in a patent lawsuit against Pfizer, concerning the pneumococcal vaccine. The company won the backing of the Korean Supreme Court, bringing an end to the long-standing dispute. The court’s decision confirms...